Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes

被引：0
|
作者：
Fenaux, P.
Mufti, G. J.
Hellstrom-Lindberg, E.
机构：
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2009年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [1] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    不详
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (02) : 120 - 120
  • [2] Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
    Navada, Shyamala C.
    Silverman, Lewis R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (01) : 21 - 27
  • [3] Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
    Bernal, T.
    Martinez-Camblor, P.
    Sanchez-Garcia, J.
    de Paz, R.
    Luno, E.
    Nomdedeu, B.
    Ardanaz, M. T.
    Pedro, C.
    Amigo, M. L.
    Xicoy, B.
    del Canizo, C.
    Tormo, M.
    Bargay, J.
    Valcarcel, D.
    Brunet, S.
    Benlloch, L.
    Sanz, G.
    LEUKEMIA, 2015, 29 (09) : 1875 - 1881
  • [4] Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
    T Bernal
    P Martínez-Camblor
    J Sánchez-García
    R de Paz
    E Luño
    B Nomdedeu
    M T Ardanaz
    C Pedro
    M L Amigo
    B Xicoy
    C del Cañizo
    M Tormo
    J Bargay
    D Valcárcel
    S Brunet
    L Benlloch
    G Sanz
    Leukemia, 2015, 29 : 1875 - 1881
  • [5] Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine
    Laribi, Kamel
    Bolle, Delphine
    Alani, Mustafa
    Ghnaya, Habib
    Besancon, Anne
    Farhi, Jonathan
    Mheidly, Kayane
    Denizon, Nathalie
    de Materre, Alix Baugier
    CANCER MEDICINE, 2019, 8 (05): : 2188 - 2195
  • [6] Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes
    Fujimaki, Katsumichi
    Miyashita, Kazuho
    Kawasaki, Rika
    Tomita, Naoto
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (03) : 228 - 231
  • [7] Efficacy and Safety of a 5-Day Regimen of Azacitidine for Patients with High-Risk Myelodysplastic Syndromes
    Fujimaki, Katsumichi
    Miyashita, Kazuho
    Kawasaki, Rika
    Tomita, Naoto
    Ishigatsubo, Yoshiaki
    BLOOD, 2014, 124 (21)
  • [8] GLOBAL DNA METHYLATION PREDICTS THE RESPONSIVENESS TO AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Poloni, A.
    Goteri, G.
    Zizzi, A.
    Serrani, F.
    Costantini, B.
    Trappolini, S.
    Mariani, M.
    Leoni, P.
    HAEMATOLOGICA, 2012, 97 : 133 - 133
  • [9] Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2009, 33 : S7 - S11
  • [10] Treatment of patients with high-risk myelodysplastic syndromes
    Gattermann, Norbert
    Kuendgen, Andrea
    Germing, Ulrich
    CANCER TREATMENT REVIEWS, 2007, 33 : S64 - S68
12345